New lung cancer drug introduces by Beacon.

Beacon launched Brigatinib under the brand name of Briganix. It is a tablet preparation which is available in two strength 90 mg and 180 mg respectively.

 It is indicated for the treatment of patients with non small cell lung cancer who have progressed on or are intolerant to Crizotinib.

To know more visit our product website : www.briganix.com